ClinicalTrials.gg
RecruitingNCT07509099Updated Oct 2, 2026

Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

A Phase 3 interventional study of cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy and PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy in Squamous Cell Carcinoma of Head and Neck, sponsored by Ji Dongmei. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Ji Dongmei · Phase 3, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 2, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 291 studies in Squamous Cell Carcinoma of Head and Neck with a site in China — 172 open to participants now, 205 under way, 25 of them phase 3. Squamous Cell Carcinoma of Head and Neck · China.

Planned enrollment
35th of 266
316 · median 66
Started
2026
with 54 others
Phase 3
32 of 291
21 open now
Primary completion
2031-09
later than 201 of 204 live
Registered
250th of 291
by date

Among the 291 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, this one is the 35th largest by planned enrollment of the 266 interventional ones that give a count, is one of 55 that started in 2026, is one of 32 in phase 3, reaches primary completion later than 201 of the 204 other live ones, and was the 250th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

172 of the 291 studies in Squamous Cell Carcinoma of Head and Neck with a site in China are open now. Recruiting first, the newest first:

166 more — sign in →

All 172 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, or all of them as a file.
02

Study summary

This is an open-label, randomized, prospective, multicenter phase III trial to evaluate the efficacy and safety of the combination therapy of cetuximab with either pembrolizumab or finotonlimab, alongside chemotherapy, as a first-line treatment, compared with pembrolizumab or finotonlimab with chemotherapy for R/M HNSCC.

Read the detailed description

Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who are not candidates for curative-intent therapies have a poor prognosis.

Currently, the standard treatment involves a combination of cetuximab with chemotherapy or a PD-1 inhibitor-based regimen.

This study is an open-label, randomized, prospective, multicenter phase III trial requiring a total of 316 R/M HNSCC patients. Participants will be randomized into either the experimental group or the control group. The stratification factors include the choice of PD-1 inhibitor (pembrolizumab versus finotonlimab) and the primary tumor site (oral cavity, hypopharynx, or others).

Patients in the experimental group will receive cetuximab along with either pembrolizumab or finotonlimab, nab-paclitaxel, and cisplatin. Those in the control group will receive either pembrolizumab or finotonlimab, nab-paclitaxel, and cisplatin.

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-70 years;
  2. Performance Status 0 or 1;
  3. confirmed diagnosis of head and neck squamous cell carcinoma;
  4. Subjects with distant or local recurrence not suitable for curative treatment; local recurrence patients must have previously received radiotherapy (postoperative or radical);
  5. No prior systemic chemotherapy; subjects who have ceased chemotherapy for locally advanced disease as part of multidisciplinary treatment for more than 6 months may be enrolled;
  6. At least one available for evaluation by enhanced CT or MRI according to 1.1;
  7. Adequate organ function:
  8. Estimated survival greater than 3 months;
  9. Voluntary signing of form, with good compliance expected, and ability to follow up as required by the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Nasopharyngeal carcinoma;
  2. Known allergic reaction against any of the components of the trial treatment;
  3. a. Previous treatment with (ICIs) (Prior receipt of ICIs is allowed if they were given as part of curative-intent therapy, with more than 6 months between the last dose and disease recurrence, or as adjuvant ICI monotherapy that achieved disease control for over 6 months); b. Previous treatment with cetuximab (Prior receipt of cetuximab is allowed if they were given as part of curative-intent therapy, with more than 6 months between the last dose and disease recurrence); c.Previous treatment with chemotherapy (Prior receipt of chemotherapy is allowed if they were given as part of curative-intent neoadjuvant and adjuvant therapy, with more than 6 months between the last dose and disease recurrence) The end date of the therapies mentioned above is the date of the last administration.
  4. heart disease, including severe heart failure: heart failure class III\~IV, ischemic heart disease (e.g., myocardial infarction or angina), acute myocardial infarction or congestive heart failure or greater than 500 ms within the last 6 months;
  5. Undergoing or expected to undergo secondary or higher surgeries within three weeks prior to the first dose;
  6. diseases requiring treatment or a history of syndromes requiring systemic use of or , such as pituitary inflammation, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism, hypothyroidism, etc.;
  7. Other serious uncontrolled concomitant diseases affecting protocol compliance or result interfere, including uncontrolled diabetes or pulmonary diseases (interstitial pneumonia, obstructive lung disease, and symptomatic bronchospasm history);
  8. Known active central nervous system and/or ; Note: Subjects with previously treated may participate provided they are stable (without evidence of progression by imaging (using the identical imaging modality for each assessment, either MRI or CT scan) for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
  9. (HBV) (HBsAg positive and HBV-DNA≥ 103 IU/ml), (HCV) infection (HCV antibody positive and detectable HCV-RNA); and other acquired or congenital immunodeficiency diseases, including but not limited to infection;
  10. Pregnant or breastfeeding women, or women planning to conceive during treatment and within 6 months after the last dose of study medication. Fertile women and sexually active men unwilling to use highly effective during the study and for 6 months afterward.
  11. Severe active infections;
  12. Severe neurological or psychiatric history, including dementia or epilepsy;
  13. Drug abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the trial or the assessment of results;
  14. Other reasons deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    cetuximab + PD-1 mAb + chemotherapy

    Drug: cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy

  • Active comparator
    Control Group

    PD-1 mAb + chemotherapy

    Drug: PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy

Interventions

  • Drugcetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy

    Cetuximab: 400 mg/m2 initial dose followed by 250 mg/m2 (weekly), iv, until disease progression, intolerable toxicity, or the subject voluntarily requests to discontinue the trial treatment. Pembrolizumab or Finotonlimab:200mg, iv, administered on Day 1, Q3W, until disease progression, intolerable toxicity, or the subject voluntarily requests to discontinue the trial treatment. Nab-paclitaxel: 260 mg/m², iv over 30 minutes, administered on Day 1, Q3W, for a maximum of 6 cycles. Cisplatin: 75 mg/m², iv (hydration), administered on Day 1, repeated Q3W (if cisplatin-related non-hematological toxicity occurs, treatment may switch to carboplatin area under the curve(AUC)=5; if cisplatin intolerant patients, carboplatin(AUC=5) could be used), for a maximum of 6 cycles.

  • DrugPD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy

    Pembrolizumab or Finotonlimab:200mg, iv, administered on Day 1, Q3W, until disease progression, intolerable toxicity, or the subject voluntarily requests to discontinue the trial treatment. Nab-paclitaxel: 260 mg/m², iv over 30 minutes, administered on Day 1, Q3W, for a maximum of 6 cycles. Cisplatin: 75 mg/m², iv (hydration), administered on Day 1, repeated Q3W (if cisplatin-related non-hematological toxicity occurs, treatment may switch to carboplatin area under the curve(AUC)=5; if cisplatin intolerant patients, carboplatin(AUC=5) could be used), for a maximum of 6 cycles.

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Expected 51 months following the First Subject First Visit (FSFV)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Disease Control Rate (DCR), Duration of Response (DoR), Time to Response (TTR), Overall Survival (OS)

    Time frame: Expected 51 months following the First Subject First Visit (FSFV)

  2. Disease Control Rate (DCR)

    The disease control rate (DCR) is defined as the proportion of subjects in the full analysis set (FAS) whose best overall response is either complete response (CR), partial response (PR), or stable disease (SD) based on investigator assessment using RECIST v1.1. Subjects with SD must have maintained SD for at least 6 weeks from the first dose to be counted as disease control.

    Time frame: Expected 51 months following the First Subject First Visit (FSFV)

  3. Duration of Response (DoR)

    The time from the first documented evidence of objective response (CR or PR) to the first documented disease progression or death from any cause, whichever occurred first.

    Time frame: Expected 51 months following the First Subject First Visit (FSFV)

  4. Time to Response (TTR)

    The time from the date of randomization to the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) in patients who ultimately achieve a response.

    Time frame: Expected 51 months following the First Subject First Visit (FSFV)

  5. Overall Survival (OS)

    The time from randomization to death from any cause.

    Time frame: Expected 51 months following the First Subject First Visit (FSFV)

  6. Safety Endpoints

    Incidence and severity of adverse events (AEs) and serious adverse events (SAE), including abnormalities in vital signs, electrocardiograms, and laboratory tests.

    Time frame: Expected 51 months following the First Subject First Visit (FSFV)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2031, 60 months after the start.

Of 51 non-industry phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 67 and three quarters within 121. This study's planned 60 months is below that.

Counting every sponsor, half of 78 studies reached it within 76 months; a quarter within 38 and three quarters within 117.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 3, 2026
StartActual
Sep 15, 2026
Primary completionEst.
Sep 30, 2031
CompletionEst.
Sep 30, 2031
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
1 site added. Fudan University Shanghai Cancer Center is now Recruiting
Show site
  • Fudan University Shanghai Cancer Center · Shanghai, China
Oct 2, 2026
Start date
Sep 30, 2026→Sep 15, 2026 (actual)
Oct 2, 2026
Contact
Study contact changed: j•••@163.com · •••3928→j•••@163.com · •••8900; added y•••@163.com · •••8900. See the current contact
Oct 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Fudan University Shanghai Cancer Center · Shanghai, ChinaContact j•••@163.com · •••3928→j•••@hotmail.com · •••8900Contact added y•••@163.com
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Recruiting
    1 site added. Fudan University Shanghai Cancer Center is now Recruiting
    Show site
    • Fudan University Shanghai Cancer Center · Shanghai, China
    Start date Sep 30, 2026→Sep 15, 2026 (now actual)
    Contact Study contact changed: j•••@163.com · •••3928→j•••@163.com · •••8900; added y•••@163.com · •••8900. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Fudan University Shanghai Cancer Center · Shanghai, ChinaContact j•••@163.com · •••3928→j•••@hotmail.com · •••8900Contact added y•••@163.com

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07509099
Lead sponsor
Ji Dongmei
Responsible party
Ji Dongmei (Doctor, Fudan University) — Sponsor-investigator
First posted
Apr 3, 2026
Start date
Sep 15, 2026
Primary completion
Sep 30, 2031 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Oct 2, 2026

Study contacts

Dongmei Ji, Doctor
Contact
jidm2025@163.com
+86 021 64175590 88900
Youzhou Sang, Doctor
Contact
youzhousang@163.com
+86 021 64175590 88900

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion